Lilly Inks R&D Deal With Indian Firm Potentially Worth $100 Million
This article was originally published in PharmAsia News
Executive Summary
Lilly's research and development agreement with India-based Nicholas Piramal India Limited gives the Indian firm the potential to earn $100 million in milestones and call-back payments, the firms said Jan. 12
You may also be interested in...
Deals Of The Week: UCB/Wilex, J&J/Vanderbilt, Alnylam/Cubist ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: UCB/Wilex, J&J/Vanderbilt, Alnylam/Cubist ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Eli Lilly In Asia Expansion Overdrive
SHANGHAI - Eli Lilly opened a brand new Asian office and unveiled a major expansion at a second office in as many days as part of a company-wide shift to a new collaborative research and development model, company officials told PharmAsia News